1968 - 2020
1968

Lupin commences business

1972

Lupin Laboratories Pvt. Ltd. is incorporated

1979

First Formulation Plant and R&D Center at Aurangabad is commissioned

1981

Production of Ethambutol API starts

1987

The Cephalexin plant at Mandideep and 7 ADCA plants at Ankleshwar go on stream

1988

Lupin Human Welfare and Research Foundation (LHWRF) is founded by Desh Bandhu Gupta

1989

Joint Venture in Thailand is established

USFDA approvals for Ankleshwar and Mandideep plants received

1991

Initiates production of Injectable Cephalosporins (API and Finished Product) at Mandideep

1992

Fermentation Plant at Lupin Chemicals Ltd. Tarapur, Maharashtra established

Commissions Sterile Plant for Injectable Cephalosporins (API) at Mandideep

1993

IPO of Lupin Laboratories Ltd. and Lupin Chemicals Ltd.

1997

USFDA approval for Cefaclor at Mandideep, 7 ACCA at Ankleshwar and Rifampicin at Tarapur

1998

UK MCA approval for the Injectable Cephalosporin Finished Product Plant at Mandideep

1999

UK MCA approval for the Injectable Cephalosporin API plant at Mandideep

2000

USFDA approval for Injectable Cefotaxime (API and Finished Product) at Mandideep

2001

State-Of-The-Art R&D center, Lupin Research Park at Pune commissioned

Supply of Cephalosporin Finished Product to Alliance Partners in the US commences

Lupin Laboratories Ltd. is amalgamated with Lupin Chemicals Ltd., and retitled Lupin Ltd.

2002

Exports to Advanced Markets cross INR 1000 Million

Patent filings cross 100

First 5 ANDAs filed

New Anti-TB Facility commissioned at Aurangabad

Rablet® rated by ORG-Marg as the second best launch in India in FY 2002-03

2003

WHO approval for finished product facility at Aurangabad

SAP ERP implemented across the company to unify all business functions and processes

USFDA approval for the Oral Cephalosporin Plant at Mandideep

Lupin Pharmaceuticals Inc. USA, formed for commercialization activities in the US

2004

Commences US Branded Business with the launch of Suprax®

2005

Generics Business launched in the US with first 4 Products

USFDA approval for New Lovastatin Plant at Tarapur

USFDA approval for Goa finished product facility

Maiden Employees Stock Option Plan launched

2006

UK MHRA and WHO approval for Goa finished product facility

Maiden bonus shares issued in the ratio of 1:1

Maiden Issue of Foreign Currency Convertible Bonds aggregating USD 100 Million

2007

Acquired Kyowa Pharmaceutical Industry Company Ltd., a leading Generics Company in Japan

Vadodara based Rubamin Laboratories Ltd. acquired

Starts commercial production at the new finished product facility at Jammu

2008

Biotech Facility in Pune set up

Acquired Hormosan Pharma Gmbh in Germany

Majority stake in Generic Health Pty Ltd., Australia acquired

Acquired majority stake in Pharma Dynamics, South Africa

2009

Acquired the US Rights for Antara®

Majority stake in Multicare
Pharmaceuticals Philippines Inc. acquired

India Region Formulations (IRF) business crosses INR 1,000 Cr.

2011

Commercial Production at the New Oral

Solid Dosage Facility at Pithampur commences

Acquires I’Rom Pharmaceuticals in Japan

India Formulations business inks its first in-license deal with Huminsulin®

2012

Enters the Nifty 50 Index

2013

Tonact® became the first Lupin brand to cross INR 100 Cr.

2014

Joint Venture Agreement with Yoshindo Inc. in Japan to launch biosimilars

Acquires Laboratorios Grin, Mexico, Specialty Ophthalmic Company and with this enters the Latin American Market

Acquires Nanomi B.V. to enter the Complex Injectables Space

2015

Center of Excellence for Inhalation Research in Coral Springs Florida inaugurated

Acquires Specialty Product Portfolio of Temmler Pharma GmbH & Co. in Germany

Acquires Medquimica Industria Farmaceutica S.A. in Brazil

Completes the acquisition of Pharma Dynamics in South Africa

2016

India Formulations business crosses INR 3,000 Cr.

Bolsters the US Brands Portfolio with Methergine® Oral Tablets

Acquires Branded Product Portfolio from Shionogi & Co. Ltd. in Japan

Completes acquisition of US based GAVIS Pharmaceuticals LLC and Novel Laboratories Inc. (GAVIS)

2017

Commissions new plant at Tottori, Japan

Forays into the OTC Segment with pan-India launch of Softovac®

Inaugurates a new plant at Sikkim

The number of sales representatives in India Formulations business crosses the 5,000 mark

2018

Acquires Symbiomix Therapeutics, LLC in New Jersey for launch of Solosec®

Commissions Injectables Facility at Nagpur

Files New Drug Application for Etanercept Biosimilar in Japan

Signs deal with AbbVie for exclusive rights to develop and commercialize Lupin’s MALT1 inhibitors (oncology)

2019

Inks partnership with Boehringer Ingelheim to develop and commercialize Lupin’s MEK inhibitors (oncology)

Orphan Drug NaMuscla® for treatment of non-dystrophic Myotonia launched in Europe

2020

Receives European Marketing Authorization for Nepexto, Biosimilar Etanercept

Receives International Sustainability Rating System (ISRS) Certification for 4 sites

2021

India Formulations business crosses INR 5,000 Cr.